Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 May;75(5):1078-1080.
doi: 10.1002/hep.32319. Epub 2022 Jan 22.

The rise and fall and rise again of ammonia as a therapeutic target in HE

Thomas H Tranah  1   2 , Debbie L Shawcross  1   2
Affiliations
Editorial

The rise and fall and rise again of ammonia as a therapeutic target in HE

Thomas H Tranah et al. Hepatology. 2022 May.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Tranah TH, Paolino A, Shawcross DL. Pathophysiological mechanisms of hepatic encephalopathy. Clin Liver Dis. 2015;5:59–63.
    1. Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, et al. Infection and systemic inflammation, not ammonia, are associated with grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol. 2011;54:640–9.
    1. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open‐label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137:885–91.e1.
    1. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–81.
    1. Patel VC, Lee S, McPhail MJW, Da Silva K, Guilly S, Zamalloa A, et al. Rifaximin‐alpha reduces gut‐derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. J Hepatol. 2021 Sep 24. https://doi.org/10.1016/j.jhep.2021.09.101 . [Epub ahead of print] - DOI

LinkOut - more resources